论文部分内容阅读
【目的】对比吉西他滨与长春瑞滨分别联合顺铂治疗晚期乳腺癌的临床疗效。【方法】选取对蒽环类和紫杉类药物耐药的晚期乳腺癌者70例，根据化疗方案不同分为吉西他滨（GEM ）联合顺铂（DDP）（GP组）和长春瑞滨（NVB）联合DDP（NP组），每组35例。治疗2个周期后，比较两组患者的临床疗效及不良反应。【结果】G P组治疗有效率、疾病控制率分别为62．9％、82．9％，与N P组54．3％、77．1％比较差异无统计学意义（ P ＞0．05）。两种化疗方案均出现了不同程度的不良反应，其中 GP组发生Ⅲ／Ⅳ度白细胞减少（25．7％）及血小板减少（34．3％）显著高于N P组（11．4％，14．3％）（ P ＜0．05）；而静脉炎的发生率（28．6％） GP组显著低于NP组（45．7％）（ P＜0．05）。【结论】GEM联合DDP与NVB联合DDP治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的临床疗效相当，且均未见严重不良反应。“,”[Objective] To compare the efficacy of gemcitabine versus vinorelbine plus cisplatin in the treatment of advanced breast cancer .[Methods] A total of 70 advanced breast patients not responding to an‐thracycline and/or taxane were selected from June 2013 to June 2014 .According to different chemotherapeutic regimens ,they were divided into gemcitabine (GEM ) plus cisplatin (DDP) group (GP group) and vinorelbine (NVB) plus cisplatin (DDP) (NP group) (n=35 each) .After two cycles of treatment ,clinical efficacy and adverse reactions were compared between two groups .[Results] The response and disease control rates were 62 .9% and 82 .9% in GP group versus 54 .3% and 77 .1% in NP group .No significant inter‐group differences existed in response rate and disease control rate ( P>0 .05) .There were different degrees of adverse reactions in two groups .The Ⅲ /Ⅳ degree incidence of neutropenia (25 .7% ) and the incidence of phlebitis (34 .3% ) of GP group was significantly higher than those of NP group (11 .4% ,14 .3% ) .The differences were statistical‐ly significant ( P <0 .05) .And the incidence of thrombocytopenia was significantly lower in GP group than that in NP group (28 .6% vs 45 .7% ,P<0 .05) .[Conclusion]Gemcitabine plus cisplatin and vinorelbine plus cisplatin are equally efficacious in the treatment of advanced breast cancer .There is no onset of serious adverse reactions .